Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company specializing in treatments for central nervous system (CNS) disorders, has announced positive results from Study 304, which evaluated the efficacy and safety…
BridgeBio Pharma, Inc. (Nasdaq: BBIO), an innovative biopharmaceutical company focused on treating genetic diseases, has announced the publication of a case study, “Applications of Portfolio Theory to Accelerating Biomedical Innovation,”…
Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) have announced a $350 million synthetic royalty funding agreement, tied to the U.S. net sales of Niktimvo (axatilimab-csfr). “We are…
BioNTech SE (Nasdaq: BNTX) has announced its financial results for the third quarter and the first nine months of 2024, alongside updates on its corporate initiatives. During this period, the…
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, has announced the appointment of Alan Bash as the President of CARVYKTI®. In this newly established position, Mr. Bash…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) showcased findings from the long-term KINECT®-4 study, revealing that nearly 60% of participants achieved remission from tardive dyskinesia after 48 weeks of treatment with once-daily…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the launch of a new disease awareness campaign titled “We’ll Get There Soon” on FCS Awareness Day. The initiative aims to raise awareness…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) recently presented data from over 300 patients with tardive dyskinesia treated with INGREZZA® (valbenazine) capsules, revealing significant improvements in functional, social, emotional, and health-related quality…
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted therapy for preventing hereditary…
A recent World Health Organization (WHO) study, published in eBioMedicine, has identified 17 priority pathogens that are endemic in various communities and urgently require new vaccines. This marks WHO’s first…
Libra Therapeutics, Inc., a private biotechnology company focused on developing innovative therapies to restore cellular balance and reduce neurodegeneration, has announced the appointment of Shawn A. Scranton, PharmD, as President…
Kashiv BioSciences, LLC, a globally integrated biopharmaceutical company, has appointed Dr. Sandeep Nilkanth Athalye as its new Global Chief Executive Officer. With over 20 years of experience in strategic and…